Wilhelmus Cm  Groenhuysen net worth and biography

Wilhelmus Groenhuysen Biography and Net Worth

COO of NovoCure
Wilco Groenhuysen has served as Novocure’s Chief Operating Officer since September 2020. He is responsible for the general and administrative management of the company, the strategic and operational leadership of Novocure’s supply chain, warehousing and distribution, quality assurance and information technology operations. Mr. Groenhuysen is tasked to ensure organizational readiness in anticipation of the completion of four phase 3 clinical trials over the next few years.

From January 2012 to August 2020, Mr. Groenhuysen served as the Company’s Chief Financial Officer. He has served on the Board of Optinose Inc., a commercial-stage specialty pharmaceuticals company, since October 2017. From 2007 to 2011, Mr. Groenhuysen worked for Cephalon, Inc., a U.S. biopharmaceutical company, last serving as executive vice president and chief financial officer, where he had responsibility for worldwide finance, commercial operations and risk management. From 1987 to 2007, Mr. Groenhuysen worked for Philips Group in various assignments in Europe, Asia and the United States, the latest of which started in 2002 when he was promoted to chief financial officer and senior vice president of Philips Electronics North America Corporation. Mr. Groenhuysen holds a Master’s Degree in Business Economics from VU University Amsterdam and graduated as a Registered Public Controller at VU University Amsterdam.

What is Wilhelmus Cm Groenhuysen's net worth?

The estimated net worth of Wilhelmus Cm Groenhuysen is at least $5.53 million as of March 4th, 2024. Mr. Groenhuysen owns 251,235 shares of NovoCure stock worth more than $5,529,682 as of May 29th. This net worth evaluation does not reflect any other investments that Mr. Groenhuysen may own. Additionally, Mr. Groenhuysen receives an annual salary of $1,010,000.00 as COO at NovoCure. Learn More about Wilhelmus Cm Groenhuysen's net worth.

How old is Wilhelmus Cm Groenhuysen?

Mr. Groenhuysen is currently 66 years old. There are 7 older executives and no younger executives at NovoCure. The oldest executive at NovoCure is Prof. Yoram Palti M.D., Ph.D., Founder & CTO, who is 86 years old. Learn More on Wilhelmus Cm Groenhuysen's age.

What is Wilhelmus Cm Groenhuysen's salary?

As the COO of NovoCure Limited, Mr. Groenhuysen earns $1,010,000.00 per year. There are 2 executives that earn more than Mr. Groenhuysen. The highest earning executive at NovoCure is Mr. Asaf Danziger, CEO & Director, who commands a salary of $1,700,000.00 per year. Learn More on Wilhelmus Cm Groenhuysen's salary.

How do I contact Wilhelmus Cm Groenhuysen?

The corporate mailing address for Mr. Groenhuysen and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected]. Learn More on Wilhelmus Cm Groenhuysen's contact information.

Has Wilhelmus Cm Groenhuysen been buying or selling shares of NovoCure?

Wilhelmus Cm Groenhuysen has not been actively trading shares of NovoCure during the last quarter. Most recently, Wilhelmus Cm Groenhuysen sold 1,217 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $16.01, for a transaction totalling $19,484.17. Following the completion of the sale, the chief operating officer now directly owns 251,235 shares of the company's stock, valued at $4,022,272.35. Learn More on Wilhelmus Cm Groenhuysen's trading history.

Who are NovoCure's active insiders?

NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Pritesh Shah (Insider), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.

Are insiders buying or selling shares of NovoCure?

During the last twelve months, insiders at the medical equipment provider sold shares 9 times. They sold a total of 9,753 shares worth more than $163,632.37. The most recent insider tranaction occured on March, 4th when EVP Frank X Leonard sold 840 shares worth more than $13,448.40. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.

Information on this page was last updated on 3/4/2024.

Wilhelmus Cm Groenhuysen Insider Trading History at NovoCure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/4/2024Sell1,217$16.01$19,484.17251,235View SEC Filing Icon  
3/1/2024Sell2,107$16.03$33,775.21252,452View SEC Filing Icon  
9/1/2023Sell294$21.82$6,415.08209,825View SEC Filing Icon  
3/1/2023Sell2,164$76.36$165,243.04184,615View SEC Filing Icon  
3/8/2022Sell2,923$70.10$204,902.30View SEC Filing Icon  
3/3/2022Sell1,301$74.50$96,924.50View SEC Filing Icon  
9/2/2021Sell181$138.23$25,019.63View SEC Filing Icon  
2/28/2021Sell3,670$72.22$265,047.40150,014View SEC Filing Icon  
9/17/2020Sell12,500$108.60$1,357,500.00144,540View SEC Filing Icon  
9/15/2020Sell50,868$103.27$5,253,138.36155,107View SEC Filing Icon  
2/25/2020Sell18,908$81.16$1,534,573.28130,676View SEC Filing Icon  
1/22/2020Sell2,915$98.14$286,078.1088,858View SEC Filing Icon  
11/14/2019Sell27,576$81.87$2,257,647.1297,179View SEC Filing Icon  
11/11/2019Sell8,600$80.13$689,118.0089,079View SEC Filing Icon  
9/24/2019Sell7,992$80.63$644,394.9689,179View SEC Filing Icon  
9/16/2019Sell25,000$78.93$1,973,250.00112,179View SEC Filing Icon  
9/12/2019Sell25,000$79.57$1,989,250.00112,179View SEC Filing Icon  
9/9/2019Sell25,000$80.83$2,020,750.00112,179View SEC Filing Icon  
3/5/2019Sell90,000$53.94$4,854,600.0085,030View SEC Filing Icon  
2/28/2019Sell3,288$53.68$176,499.8469,552View SEC Filing Icon  
1/25/2019Sell35,000$49.20$1,722,000.0072,149View SEC Filing Icon  
1/23/2019Sell35,000$47.35$1,657,250.0072,149View SEC Filing Icon  
1/18/2019Sell30,000$45.90$1,377,000.0067,149View SEC Filing Icon  
1/15/2019Sell30,000$44.20$1,326,000.0067,149View SEC Filing Icon  
1/11/2019Sell30,000$42.35$1,270,500.0037,149View SEC Filing Icon  
8/27/2018Sell35,547$40.01$1,422,235.4747,397View SEC Filing Icon  
8/24/2018Sell25,574$40.00$1,022,960.0047,397View SEC Filing Icon  
8/22/2018Sell31,179$37.67$1,174,512.9372,671View SEC Filing Icon  
8/14/2018Sell4,368$37.62$164,324.16108,118View SEC Filing Icon  
8/1/2018Sell1,241$35.01$43,447.41115,644View SEC Filing Icon  
7/27/2018Sell62,727$35.08$2,200,463.16175,602View SEC Filing Icon  
5/14/2018Sell30,470$30.04$915,318.80201,898View SEC Filing Icon  
5/11/2018Sell9,393$30.01$281,883.93201,898View SEC Filing Icon  
5/1/2018Sell30,470$27.58$840,362.60View SEC Filing Icon  
2/23/2018Sell13,351$19.83$264,750.33252,412View SEC Filing Icon  
1/9/2018Sell31,132$21.02$654,394.64240,210View SEC Filing Icon  
1/4/2018Sell28,868$21.03$607,094.04268,568View SEC Filing Icon  
See Full Table

Wilhelmus Cm Groenhuysen Buying and Selling Activity at NovoCure

This chart shows Wilhelmus Cm Groenhuysen's buying and selling at NovoCure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NovoCure Company Overview

NovoCure logo
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Read More

Today's Range

Now: $22.01
Low: $21.46
High: $22.28

50 Day Range

MA: $15.98
Low: $11.83
High: $24.05

2 Week Range

Now: $22.01
Low: $10.87
High: $82.64


1,590,275 shs

Average Volume

1,359,288 shs

Market Capitalization

$2.37 billion

P/E Ratio


Dividend Yield